ALKEM
Alkem Laboratories Limited (ALKEM) Stock Analysis
Alkem Laboratories Limited is a leading Indian pharmaceutical company with strong domestic branding and exports. It markets generics across therapies including anti-infectives, gastro, and chronic care. The company manufactures from multiple plants in India and sells in regulated markets. It is a large-cap listed pharma stock.
Healthcare › Drug Manufacturers - Specialty & Generic
₹5,050.00
-4.34% 1W | -8.30% 52W
Market Cap
60.4k CR
P/E Ratio
28
52W High
₹5933.5
52W Low
₹5042
Div. Yield
0.39%
Beta
0.3
50 DMA
₹5305.6
200 DMA
₹5465.8
Profit Margin
14.3%
Inst. Own.
28.3%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,968 | 3,440 | 3,324 | 2,936 | 3,032 | 3,415 | 3,374 | 3,144 | 3,371 | 4,001 | 3,737 | 3,603 | 3,740 |
| Expenses | 2,579 | 2,693 | 2,616 | 2,534 | 2,423 | 2,662 | 2,615 | 2,752 | 2,632 | 3,080 | 2,909 | 3,086 | 2,974 |
| Operating Profit | 389 | 747 | 708 | 402 | 609 | 753 | 759 | 391 | 739 | 921 | 828 | 517 | 766 |
| OPM % | 13% | 22% | 21% | 14% | 20% | 22% | 23% | 12% | 22% | 23% | 22% | 14% | 20% |
| Other Income | 66 | 6 | 42 | 76 | 120 | 134 | 93 | 146 | 149 | 104 | 90 | 65 | 153 |
| Interest | 30 | 30 | 25 | 27 | 29 | 28 | 36 | 28 | 30 | 35 | 42 | 54 | 47 |
| Depreciation | 72 | 74 | 70 | 83 | 80 | 79 | 85 | 112 | 88 | 94 | 95 | 106 | 100 |
| Profit before tax | 353 | 648 | 655 | 367 | 619 | 780 | 731 | 396 | 771 | 896 | 781 | 423 | 772 |
| Tax % | 18% | 5% | 8% | 17% | 11% | 10% | 12% | 18% | 13% | 13% | 16% | 40% | 32% |
| Net Profit | 288 | 615 | 604 | 304 | 550 | 702 | 641 | 322 | 668 | 779 | 653 | 251 | 521 |
| EPS in Rs | 23.98 | 51.90 | 49.76 | 24.55 | 45.60 | 57.60 | 52.34 | 25.58 | 55.56 | 63.99 | 53.19 | 19.78 | 43.49 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,674 | 4,905 | 5,688 | 6,401 | 7,357 | 8,344 | 8,865 | 10,634 | 11,599 | 12,668 | 12,965 | 14,712 | 15,081 |
| Expenses | 3,248 | 4,038 | 4,687 | 5,392 | 6,237 | 6,868 | 6,920 | 8,580 | 9,977 | 10,419 | 10,452 | 11,706 | 12,049 |
| Operating Profit | 427 | 866 | 1,001 | 1,009 | 1,120 | 1,476 | 1,945 | 2,054 | 1,622 | 2,249 | 2,512 | 3,007 | 3,032 |
| OPM % | 12% | 18% | 18% | 16% | 15% | 18% | 22% | 19% | 14% | 18% | 19% | 20% | 20% |
| Other Income | 176 | 227 | 110 | 115 | 82 | 102 | 230 | 146 | 101 | 186 | 494 | 407 | 412 |
| Interest | 81 | 71 | 45 | 55 | 55 | 65 | 59 | 52 | 107 | 112 | 122 | 161 | 178 |
| Depreciation | 71 | 93 | 101 | 143 | 193 | 253 | 275 | 304 | 310 | 299 | 357 | 382 | 395 |
| Profit before tax | 451 | 928 | 965 | 926 | 955 | 1,260 | 1,842 | 1,844 | 1,305 | 2,023 | 2,527 | 2,871 | 2,872 |
| Tax % | 13% | 19% | 6% | 31% | 19% | 9% | 12% | 9% | 23% | 10% | 12% | 18% | |
| Net Profit | 392 | 752 | 905 | 638 | 774 | 1,149 | 1,618 | 1,680 | 1,007 | 1,811 | 2,215 | 2,351 | 2,204 |
| EPS in Rs | 32.75 | 62.02 | 74.61 | 52.77 | 63.61 | 94.26 | 132.57 | 137.63 | 82.31 | 150.19 | 181.11 | 192.51 | 180.45 |
| Dividend Payout % | 12% | 20% | 20% | 25% | 25% | 27% | 23% | 25% | 61% | 27% | 25% | 28% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 8.0% | 11.0% | 12.0% |
| Profit CAGR | 32.0% | 9.0% | 12.0% |
Shareholding Pattern
Promoters53.04%
FIIs9.11%
DIIs21.80%
Public16.05%
Promoters51.20%
FIIs9.47%
DIIs21.93%
Public17.39%
Promoters51.20%
FIIs9.97%
DIIs21.54%
Public17.30%
Promoters51.20%
FIIs10.15%
DIIs21.39%
Public17.25%
Promoters49.70%
FIIs10.42%
DIIs22.64%
Public17.25%
Promoters57.16%
FIIs4.44%
DIIs16.69%
Public21.69%
Promoters56.74%
FIIs9.11%
DIIs15.63%
Public18.51%
Promoters55.13%
FIIs9.40%
DIIs19.42%
Public16.05%
Promoters51.20%
FIIs10.15%
DIIs21.39%
Public17.25%
Promoters49.70%
FIIs10.42%
DIIs22.64%
Public17.25%
ALKEM
Holdings Analysis
Key strengths & risk signals
67
Overall
75
Fundamental
59
Technical
Risks (4)
NEGLIGIBLE DIVIDEND! 0.39% yield - little to no income.
WEAK POSITION! Current price (5050.0) is below both moving averages.
WEAK! Trading at 0.9% of 52W range - near yearly lows.
NEGATIVE MOMENTUM! Price declined across timeframes - down 4.3% (1 week), 2.4% (1 month), 9.2% (3 months).
Strengths (4)
UNDERVALUED! PEG of 0.86 indicates stock is cheap relative to growth.
BULLISH SENTIMENT! In last 30 days: 12 up days, 18 down days. Avg volume on up days: 199,422 vs down days: 117,657. Ratio: 1.69x
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
APPROACHING OVERSOLD! RSI at 38.1 - watch for reversal.
Fundamental & Technical Analysis
67Overall
75Fundamental
59Technical
Fundamental Breakdown
Growth Quality
23/30
Revenue CAGR: 8.3% (MODERATE, 8/15). Profit CAGR: 32.7% (EXCELLENT, 15/15).
Profit Margin
5/10
DECENT EFFICIENCY! 14.3% profit margin - acceptable profitability.
PEG Valuation
10/10
UNDERVALUED! PEG of 0.86 indicates stock is cheap relative to growth.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.39% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 20.85% public ownership - balanced ownership structure.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
3/10
BEARISH TREND! 50-day average (5305.6) is below 200-day average (5465.8) - negative signal.
Price Position
2/10
WEAK POSITION! Current price (5050.0) is below both moving averages.
Trend Pattern
10/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
3/10
WEAK YEAR! Stock declined 8.3% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 12 up days, 18 down days. Avg volume on up days: 199,422 vs down days: 117,657. Ratio: 1.69x
RSI
4/5
APPROACHING OVERSOLD! RSI at 38.1 - watch for reversal.
52W Range
1/5
WEAK! Trading at 0.9% of 52W range - near yearly lows.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 4.3% (1 week), 2.4% (1 month), 9.2% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
ALKEM
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-06-01 | Concall PDF | |
| Q3FY262026-02-16 | Concall PDF | |
| Q2FY262025-11-19 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALKEM | ₹5,050.00 | 28 | 14.3% | 8.3% | 32.7% | -8.3% | 67 | APPROACHING SUPPORT | -21.7% | +119.9% | +10.9% | +3.8% |
| GLENMARK | ₹2,226.70 | 35 | 10.1% | 13.5% | 66.1% | +20.9% | 70 | BREAKDOWN | +929.6% | +60.2% | +28.5% | +4.6% |
| ABBOTINDIA | ₹26,170.00 | 34.4 | 23.1% | 9.0% | 17.8% | -11.8% | 69 | APPROACHING RESISTANCE | +17.1% | +8.5% | +4.3% | +6.1% |
| GLAND | ₹3,043.40 | 44.4 | 16.8% | 21.3% | 9.6% | +59.2% | 83 | BREAKOUT | +47.1% | -13.6% | +19.6% | +3.3% |
| IPCALAB | ₹1,832.60 | 35.5 | 12.9% | 15.5% | 34.3% | +48.6% | 78 | BREAKDOWN | +72.3% | +34.4% | +20.8% | +16.7% |
| AJANTPHARM | ₹3,329.00 | 36.7 | 19.6% | 13.4% | 21.6% | +37.8% | 82 | BOUNCE FROM SUPPORT | +30.9% | +25.3% | +24.8% | +14.4% |
| EMCURE | ₹1,820.60 | 34.1 | 10.4% | 15.4% | 20.2% | +36.3% | 81 | BREAKDOWN | +42.0% | +20.8% | +22.8% | +4.5% |
| WOCKPHARMA | ₹1,954.90 | 77.5 | 11.2% | 7.8% | – | +46.4% | 58 | BREAKDOWN | -217.8% | -36.1% | +25.9% | -3.7% |
Data from TradeAlone · Updated daily
ALKEM News
Alkem Laboratories Limited Launches Neuceno (cenobamate) for Partial-onset Seizures Treatment2026-09-16Alkem Laboratories Limited (alkem) Launches Renocia Exo™, India’s First Patented Ginsenoside Exosome-based Hair Growth Serum2026-09-08Alkem Laboratories Limited (alkem) Reports 11% Revenue Growth in Q1fy272026-08-14Alkem Laboratories Limited (alkem) Becomes First in India to Launch Semaglutide in Single-shot Pre-filled Syringes2026-06-02Alkem Laboratories Limited (alkem) Reports Record High Ebitda, Strong Revenue Growth in Q4 & FY262026-05-28
